God  our Guide scientific research from N.I.H
cidpUSA Foundation

 cidpusa.org   

 
      Home
      Diagnosis
      Treatment
      Pathology
      Variants
      F.A.Q
      Fibromyalgia
      IVIG
      Diet anti-inflammatory
      Burning  Feet Home
      Services Page
      Chronic Fatigue
      Autoimmune diseases
      Phylates in makeup
      Bible healing
      Calicum Toxic

Mercury in makeup

     Toxic Lipstick

    Toxic Baby products

Vaginal problems

   Vaginal discharge

Viagra for women

Sex in autoimmune disease

Breast Size and disease

Vaccine aids Link

Vaccination Dangers

Vaccine Dangers

Adverse reaction to smallpox vaccine

CDC VACCINE ALERT

VACCINE INJURY RULING\

Vaccination & Autism

Smallpox Vaccination

Vaccination Guide

Vaccination Alert

Gardasil Facts

Aids world Map 

WHO caused Aids

Aids and diseases

Mycoplasma

Electronic treatments

Cure all diseases 

Electrical Stimulation Therapy
Guide to Quran Healing E-book

IVIg

 Green tea  and cancer risk

 Polio drops details

 

 

 

 

 

 

   Magnets and ageing

     Hypothyroid

   Deodorants cancer

    young women strokes

  Learning disability

   Brain

   disease

   MS

   Marfan

 

 

           Risky Therapy section
                                contact is through services link  

              All Natural treatments for all infections please read this link

Help for all skin, teeth, nail , hair  issues in services section
Please click the +1 button if you like this page Thanks
 

 
 
 
 

Bisphosphonate Therapy

 Linked to Risk for Severe

 Musculoskeletal Pain


Yael Waknine
 

           The first and only NMDA-receptor antagonist for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by over 2 million patients worldwide.

 

January 8, 2008 — Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday. Overlooking bisphosphonate therapy as a causal factor may delay diagnosis, thereby prolonging pain and/or impairment and the use of analgesics. In contrast with the acute-phase response that sometimes accompanies initial exposure to bisphosphonate therapy, some patients experience severe and sometimes incapacitating bone, joint, and/or muscle pain that begins months or years later.

The incidence rate and risk factors for this reaction remain unknown, according to an alert sent from MedWatch, the FDA's safety information and adverse event reporting program. Moreover, discontinuation of therapy may not lead to complete relief — some patients have reported slow or incomplete resolution of symptoms.

Over the next 6 months, the FDA will be evaluating reports of severe musculoskeletal pain associated with bisphosphonate use. In the interim, patients reporting these symptoms should be monitored, and alternative causes for pain should be considered for those who do not experience a lessening or resolution of symptoms after bisphosphonate withdrawal.

Bisphosphonates are indicated for the prevention and treatment of osteoporosis and for treating hypercalcemia of malignancy and Paget's disease. They also are beneficial in patients with multiple myeloma and bone metastases from solid tumors.

Currently marketed oral bisphosphonates include risedronate sodium tablets (Actonel and Actonel + Ca, Proctor & Gamble Pharmaceuticals, Inc), alendronate sodium tablets (Fosamax and Fosamax + D, Merck & Company, Inc), ibandronate sodium tablets (Boniva, Roche), etidronate disodium tablets (Didronel, Proctor & Gamble), and tiludronate disodium tablets (Skelid, sanofi-aventis US, LLC).

Injectable bisphosphonates include pamidronate disodium injection (Aredia, Novartis Pharmaceuticals Corp) and zoledronic acid injection (Reclast and Zometa, Novartis).

Adverse events related to bisphosphonate use should be reported to the FDA's MedWatch reporting program by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at http://www.fda.gov/medwatch, or by mail to 5600 Fishers Lane, Rockville, MD 20852-9787

 

 

 


 


 
           Healing    Mercury in makeup   Subcutaneous IVIg PAGE.